首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

【2h】

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

机译：65岁以上2型糖尿病患者的地格胰岛素和U100相比地格曲胰岛素胰岛素的严重心血管不良事件和较低的严重血糖：DEVOTE 7（DEVOTE 7）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsThe aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older.

机译：目的本研究的目的是描述65岁或以上年龄的2型糖尿病（T2D）患者中，以地格胰岛素（degludec）与甘精胰岛素100 units / mL（甘精胰岛素U100）相比发生心血管（CV）事件和严重低血糖的风险。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Richard E. Pratley; Scott S. Emerson; Edward Franek; Matthew P. Gilbert; Steven P. Marso; Darren K. McGuire; Thomas R. Pieber; Bernard Zinman; Charlotte T. Hansen; Melissa V. Hansen; Thomas Mark; Alan C. Moses; John B. Buse;
展开▼
作者单位

展开▼
年(卷),期 -1(21),7
年度 -1
页码 1625–1633
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
basal insulin cardiovascular disease hypoglycaemia type 2 diabetes;

机译：基础胰岛素;心血管疾病;低血糖;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) [J] . Pratley Richard E., Emerson Scott S., Franek Edward, Diabetes, obesity & metabolism . 2019,第7期

机译：心血管安全性和胰岛素Degludec患者患者胰岛素Degludec与胰岛素冰柱U100患者65岁或以上患者的胰岛素安全性和胰岛素肺碱U100：奉献（Devote 7）的结果
2. Cardiovascular Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (≥65 Years) with Type 2 Diabetes: Observations From DEVOTE [J] . Richard E. Pratley, Scott S. Emerson, Edward Franek, Canadian journal of diabetes . 2018,第5期

机译：心血管安全性和严重的低血糖血症的胰岛素Degludec与胰岛素狼狼U100在老年患者（≥65岁）中，患有2型糖尿病：奉献的观察
3. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) DEVOTE 1 [J] . Marso Steven P., McGuire Darren K., Zinman Bernard, The American heart journal . 2016,第期

机译：奉献设计（试验比较胰岛素Degludec的心血管安全性VS胰岛素糖尿病患者患有2型糖尿病心血管事件的患者）奉献1
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Severe Hypoglycemia, Risk of Recurrent Events and Weight Gain on Insulin Therapy in Patients with Type 1 Diabetes Mellitus. [D] . Liu, Zhiwen. 2011

机译：1型糖尿病患者的严重低血糖症，复发事件的风险和胰岛素治疗的体重增加。
6. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14 [O] . Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, 2019

机译：地高胰岛素与甘精胰岛素U100联合心力衰竭治疗2型糖尿病高心血管疾病的患者：推荐14
7. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) [O] . Richard E. Pratley, Scott S. Emerson, Edward Franek, 2019

机译：胰岛素Degludec的心血管安全性和较低的严重低血基症，2型糖尿病患者65岁或以上的患者：奉献（奉献7）的结果

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

摘要

著录项

相似文献

相关主题

期刊订阅